Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus (pages 1506–1514)
F. Vincenti, S. Friman, E. Scheuermann, L. Rostaing, T. Jenssen, J. M. Campistol, K. Uchida, M. D. Pescovitz, P. Marchetti, M. Tuncer, F. Citterio, A. Wiecek, S. Chadban, M. El-Shahawy, K. Budde, N. Goto and on behalf of the DIRECT (Diabetes Incidence after Renal Transplantation: Neoral® C2 Monitoring Versus Tacrolimus) Investigators
Version of Record online: 12 MAR 2007 | DOI: 10.1111/j.1600-6143.2007.01749.x
In this 6-month, open-label, randomized, multicenter study in de novo renal transplant patients, the primary safety endpoint of new-onset diabetes after transplant or impaired fasting glucose was significantly less frequent with cyclosporine microemulsion than tacrolimus, with no significant differences in short-term outcome. See also editorial by Van Hooff in this issue on page 1435.
Vol. 8, Issue 4, 908, Version of Record online: 19 FEB 2008